Mineralys Therapeutics Inc’s filing revealed that its Director Slingsby Brian Taylor acquired Company’s shares for reported $3.5 million on Mar 13 ’25. In the deal valued at $13.50 per share,259,259 shares were bought. As a result of this transaction, Slingsby Brian Taylor now holds 8,903,838 shares worth roughly $128.75 million.
Then, Rodman David Malcom sold 11,366 shares, generating $165,185 in total proceeds. Upon selling the shares at $14.53, the Chief Medical Officer now owns 111,686 shares.
Before that, Levy Adam Scott sold 10,757 shares. Mineralys Therapeutics Inc shares valued at $129,684 were divested by the CFO and Secretary at a price of $12.06 per share. As a result of the transaction, Levy Adam Scott now holds 215,340 shares, worth roughly $3.11 million.
H.C. Wainwright initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on July 10, 2024; the price target was $30. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Wells Fargo began covering MLYS with “an Overweight” recommendation on March 07, 2023. Stifel started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Tuesday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -7.49% to $14.46. Over the last five days, the stock has gained 3.73%. Mineralys Therapeutics Inc shares have risen nearly 17.47% since the year began. Nevertheless, the stocks have risen 10.47% over the past one year. While a 52-week high of $18.38 was reached on 03/19/25, a 52-week low of $8.24 was recorded on 02/25/25. SMA at 50 days reached $13.45, while 200 days put it at $12.35.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 13.74, which if violated will result in even more drops to 13.03. On the upside, there is a resistance level at 15.48. A further resistance level may holdings at 16.51. The Relative Strength Index (RSI) on the 14-day chart is 53.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.14, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 44.04%. Stochastics %K at 81.77% indicates the stock is a selling.
The most recent change occurred on March 07, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
